Page last updated: 2024-11-02

oxidopamine and Movement Disorders

oxidopamine has been researched along with Movement Disorders in 43 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was evaluation the effect of Gallic acid on movement disorders and pallidal electrical power in animal model of Parkinson's Disease (PD)."3.77Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease. ( Farbood, Y; Mansouri, SM; Sameri, MJ; Sarkaki, A, 2011)
"One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management."2.42Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004)
"Pretreatment with genistein, an isoflavone, significantly preserved motor function in rats injected with low-dose 6-OHDA, as evaluated by the stepping and cylinder tests."1.35Preventive effects of genistein on motor dysfunction following 6-hydroxydopamine injection in ovariectomized rats. ( Kyuhou, S, 2008)
"Rats treated with bromocriptine exhibited rotational sensitisation but no AIMs."1.34The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. ( Cenci, MA; Lindgren, HS; Lundblad, M; Ohlin, KE; Rylander, D, 2007)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19907 (16.28)18.7374
1990's5 (11.63)18.2507
2000's15 (34.88)29.6817
2010's15 (34.88)24.3611
2020's1 (2.33)2.80

Authors

AuthorsStudies
Kozioł, E1
Skalicka-Woźniak, K1
Michalak, A1
Kaszubska, K1
Budzyńska, B1
Ma, Y1
Zhan, M1
OuYang, L1
Li, Y1
Chen, S1
Wu, J1
Chen, J1
Luo, C1
Lei, W1
Didonet, JJ1
Cavalcante, JC1
Souza, Lde S1
Costa, MS1
André, E1
Soares-Rachetti, Vde P1
Guerrini, R1
Calo', G1
Gavioli, EC1
Willard, AM1
Bouchard, RS1
Gittis, AH1
Lee, M1
Ryu, YH1
Cho, WG1
Kang, YW1
Lee, SJ1
Jeon, TJ1
Lyoo, CH1
Kim, CH1
Kim, DG1
Lee, K1
Choi, TH1
Choi, JY1
Czarnecka, A1
Konieczny, J1
Lenda, T1
Lorenc-Koci, E1
Esteves, AM1
Lopes, C1
Frank, MK1
Arida, RM1
Frussa-Filho, R1
Tufik, S1
de Mello, MT1
Liang, C1
Xu, Y1
Zheng, D1
Sun, X1
Xu, Q1
Duan, D1
Dupre, KB1
Eskow, KL1
Barnum, CJ1
Bishop, C1
Kyuhou, S1
Krishnamurthi, RV1
Mathai, S1
Kim, AH1
Zhang, R1
Guan, J1
Kääriäinen, TM1
García-Horsman, JA1
Piltonen, M1
Männistö, PT1
Hahn, M1
Timmer, M1
Nikkhah, G2
Young, CK1
Koke, SJ1
Kiss, ZH1
Bland, BH1
Brown, AR2
Hu, B2
Antle, MC2
Teskey, GC2
Li, XH1
Wang, JY1
Gao, G1
Chang, JY1
Woodward, DJ1
Luo, F1
O'Sullivan, DB1
Harrison, PT1
Sullivan, AM1
Sameri, MJ1
Sarkaki, A1
Farbood, Y1
Mansouri, SM1
Fleming, SM1
Schallert, T2
Ciucci, MR1
Delaville, C1
Zapata, J1
Cardoit, L1
Benazzouz, A1
Rui, G1
Guangjian, Z1
Yong, W1
Jie, F1
Yanchao, C1
Xi, J1
Fen, L1
Gittis, A1
Linazasoro, G1
Rafuse, VF1
Soundararajan, P1
Leopold, C1
Robertson, HA1
Centonze, D1
Gubellini, P1
Rossi, S1
Picconi, B1
Pisani, A1
Bernardi, G1
Calabresi, P1
Baunez, C1
de Lago, E1
Fernández-Ruiz, J1
Ortega-Gutiérrez, S1
Cabranes, A1
Pryce, G1
Baker, D1
López-Rodríguez, M1
Ramos, JA1
Matsubara, K1
Shimizu, K1
Suno, M1
Ogawa, K1
Awaya, T1
Yamada, T1
Noda, T1
Satomi, M1
Ohtaki, K1
Chiba, K1
Tasaki, Y1
Shiono, H1
Lindgren, HS1
Rylander, D1
Ohlin, KE1
Lundblad, M1
Cenci, MA1
Olsson, M1
Bentlage, C1
Björklund, A2
Byrnes, EM1
Johnson, BJ1
Bruno, JP1
Matsuura, K1
Kabuto, H1
Makino, H1
Ogawa, N1
Johnson, RE1
Becker, JB1
Campbell, BM1
Gresch, PJ1
Walker, PD1
Crocker, SJ1
Wigle, N1
Liston, P1
Thompson, CS1
Lee, CJ1
Xu, D1
Roy, S1
Nicholson, DW1
Park, DS1
MacKenzie, A1
Korneluk, RG1
Robertson, GS1
Apicella, P2
Trouche, E2
Nieoullon, A2
Legallet, E2
Dusticier, N1
Bradbury, AJ1
Costall, B1
Domeney, AM1
Jenner, PJ1
Marsden, CD2
Naylor, RJ1
Cooper, DR1
Marrel, C1
van de Waterbeemd, H1
Testa, B1
Jenner, P1
Nishino, H2
Ono, T2
Takahashi, J2
Kimura, M2
Shiosaka, S2
Yamasaki, H1
Hatanaka, H1
Tohyama, M2
Brundin, P1
Isacson, O1
Gage, FH1
Prochiantz, A1
Mintz, M1
Douglas, RJ1
Tomer, R1
de Villiers, AS1
Kellaway, L1

Reviews

2 reviews available for oxidopamine and Movement Disorders

ArticleYear
Cranial and related sensorimotor impairments in rodent models of Parkinson's disease.
    Behavioural brain research, 2012, Jun-01, Volume: 231, Issue:2

    Topics: Animals; Behavior, Animal; Brain; Brain Chemistry; Disease Models, Animal; Feeding Behavior; Mice; M

2012
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise

2004

Other Studies

41 other studies available for oxidopamine and Movement Disorders

ArticleYear
Xanthotoxin reverses Parkinson's disease-like symptoms in zebrafish larvae and mice models: a comparative study.
    Pharmacological reports : PR, 2021, Volume: 73, Issue:1

    Topics: Animals; Antiparkinson Agents; Biological Assay; Drug Discovery; Fruit; Larva; Male; Methoxsalen; Mi

2021
The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats.
    Behavioural brain research, 2014, Jun-01, Volume: 266

    Topics: Adrenergic Agents; Animals; Apomorphine; Choline O-Acetyltransferase; Cognition Disorders; Corpus St

2014
Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice.
    Behavioural brain research, 2014, Jun-01, Volume: 266

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Area Under Curve; Disease Models, Animal; Dopamine

2014
Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.
    Neuroscience, 2015, Aug-20, Volume: 301

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Chromatography, High Pressure Liquid; Di

2015
Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system.
    Synapse (New York, N.Y.), 2015, Volume: 69, Issue:9

    Topics: Animals; Brain; Depressive Disorder; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Tran

2015
The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
    Brain research, 2015, Nov-02, Volume: 1625

    Topics: Adrenergic Agents; Animals; Apomorphine; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamin

2015
Can physical exercise have a protective effect in an animal model of sleep-related movement disorder?
    Brain research, 2016, 05-15, Volume: 1639

    Topics: Animals; Brain; Disease Models, Animal; Electrocorticography; Electromyography; Exercise Therapy; Ex

2016
RNAi-mediated silencing of HLA A2 suppressed acute rejection against human fibroblast xenografts in the striatum of 6-OHDA lesioned rats.
    Journal of neuroimmunology, 2016, 08-15, Volume: 297

    Topics: Adrenergic Agents; Animals; Antigens, CD; Brain Injuries; Corpus Striatum; Disease Models, Animal; F

2016
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
    Neuropharmacology, 2008, Volume: 55, Issue:8

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine

2008
Preventive effects of genistein on motor dysfunction following 6-hydroxydopamine injection in ovariectomized rats.
    Neuroscience letters, 2008, Dec-19, Volume: 448, Issue:1

    Topics: Adrenergic Agents; Animals; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Explor

2008
A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats.
    British journal of pharmacology, 2009, Volume: 156, Issue:4

    Topics: Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Diketopiperazines;

2009
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
    Neuroreport, 2009, Feb-18, Volume: 20, Issue:3

    Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Dr

2009
Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease.
    Journal of neuroscience research, 2009, Volume: 87, Issue:9

    Topics: Animals; Brain Tissue Transplantation; Cell Communication; Cell Differentiation; Denervation; Diseas

2009
Deep brain stimulation of the posterior hypothalamic nucleus reverses akinesia in bilaterally 6-hydroxydopamine-lesioned rats.
    Neuroscience, 2009, Aug-04, Volume: 162, Issue:1

    Topics: Analysis of Variance; Animals; Avoidance Learning; Catheterization; Deep Brain Stimulation; Electrod

2009
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
    Experimental neurology, 2009, Volume: 220, Issue:1

    Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam

2009
High-frequency stimulation of the subthalamic nucleus restores neural and behavioral functions during reaction time task in a rat model of Parkinson's disease.
    Journal of neuroscience research, 2010, May-15, Volume: 88, Issue:7

    Topics: Animals; Cognition Disorders; Deep Brain Stimulation; Disease Models, Animal; Electric Stimulation T

2010
Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:5

    Topics: Animals; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Dopamine; Dyskinesia, Drug-In

2010
High frequency stimulation of the subthalamic nucleus acutely rescues motor deficits and neocortical movement representations following 6-hydroxydopamine administration in rats.
    Experimental neurology, 2011, Volume: 231, Issue:1

    Topics: Animals; Deep Brain Stimulation; Electrodes, Implanted; Male; Movement Disorders; Neocortex; Neuroto

2011
Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease.
    Pakistan journal of biological sciences : PJBS, 2011, Dec-15, Volume: 14, Issue:24

    Topics: Adrenergic Agents; Animals; Antioxidants; Disease Models, Animal; Electroencephalography; Gallic Aci

2011
Activation of subthalamic alpha 2 noradrenergic receptors induces motor deficits as a consequence of neuronal burst firing.
    Neurobiology of disease, 2012, Volume: 47, Issue:3

    Topics: Action Potentials; Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic Neurons; Anim

2012
High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats.
    Behavioural brain research, 2013, Jan-15, Volume: 237

    Topics: Acupuncture Points; Acupuncture Therapy; Analysis of Variance; Animals; Apomorphine; Biophysical Phe

2013
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
    Science (New York, N.Y.), 2012, Oct-05, Volume: 338, Issue:6103

    Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Int

2012
Neuroprotective properties of cultured neural progenitor cells are associated with the production of sonic hedgehog.
    Neuroscience, 2005, Volume: 131, Issue:4

    Topics: Animals; Antimetabolites; Blotting, Western; Bromodeoxyuridine; Cell Count; Cell Survival; Cells, Cu

2005
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
    Neuroscience, 2005, Volume: 133, Issue:3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement

2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D

2006
Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.
    Brain research, 2006, Sep-27, Volume: 1112, Issue:1

    Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain Injuries; Dopamine

2006
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
    Behavioural brain research, 2007, Feb-12, Volume: 177, Issue:1

    Topics: Analysis of Variance; Animals; Brain Injuries; Bromocriptine; Cell Count; Dopamine Agents; Dose-Resp

2007
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1995, Volume: 15, Issue:5 Pt 2

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi

1995
D1- and D2-receptor mediation of motoric behavior in rats depleted of DA as neonates: effects of age and size of depletion.
    Neuroscience letters, 1994, Nov-07, Volume: 181, Issue:1-2

    Topics: Aging; Animals; Animals, Newborn; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists;

1994
Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion.
    Journal of neuroscience methods, 1997, Apr-25, Volume: 73, Issue:1

    Topics: Animals; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred ICR; Movement Disorders; Oxidopa

1997
Akinesia and postural abnormality after unilateral dopamine depletion.
    Behavioural brain research, 1999, Volume: 104, Issue:1-2

    Topics: Animals; Behavior, Animal; Diagnostic Techniques, Neurological; Disease Models, Animal; Dopamine; Fe

1999
Neonatal dopamine depletion reveals a synergistic mechanism of mRNA regulation that is mediated by dopamine(D1) and serotonin(2) receptors and is targeted to tachykinin neurons of the dorsomedial striatum.
    Neuroscience, 2001, Volume: 105, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animals, Newborn; Dopamine; Dopamine Agonists; Dopam

2001
NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
    The European journal of neuroscience, 2001, Volume: 14, Issue:2

    Topics: Amphetamine; Amyloid beta-Protein Precursor; Animals; Antibodies; Caspase 3; Caspases; Cell Survival

2001
Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys.
    Neuroscience, 1990, Volume: 38, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Choline O-Acetyltransferase; Corpus Striatum; Dopami

1990
The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra.
    Neuroscience letters, 1986, Jun-18, Volume: 67, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic

1986
Differential time-course of reaction time recovery depending on variations in the amplitude of a goal-directed movement after nigrostriatal lesion in monkeys.
    Neuroscience letters, 1986, Jul-11, Volume: 68, Issue:1

    Topics: Animals; Brain Diseases; Caudate Nucleus; Corpus Striatum; Dopamine; Hydroxydopamines; Motor Activit

1986
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
    The Journal of pharmacy and pharmacology, 1987, Volume: 39, Issue:8

    Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; M

1987
The formation of new neuronal circuit between transplanted nigral dopamine neurons and non-immunoreactive axon terminals in the host rat caudate nucleus.
    Neuroscience letters, 1986, Feb-14, Volume: 64, Issue:1

    Topics: Animals; Brain Diseases; Dopamine; Female; Graft Survival; Hydroxydopamines; Microscopy, Electron; M

1986
Transplants in the peri- and intraventricular region grow better than those in the central parenchyma of the caudate.
    Neuroscience letters, 1986, Feb-28, Volume: 64, Issue:2

    Topics: Animals; Brain Diseases; Corpus Striatum; Dopamine; Hydroxydopamines; Mesencephalon; Methamphetamine

1986
The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting.
    Brain research, 1986, Feb-26, Volume: 366, Issue:1-2

    Topics: Amphetamine; Animals; Basal Ganglia Diseases; Corpus Striatum; Disease Models, Animal; Dopamine; Hyd

1986
Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.
    Life sciences, 1986, Jul-07, Volume: 39, Issue:1

    Topics: Amphetamine; Animals; Corpus Striatum; Desipramine; Dominance, Cerebral; Drug Tolerance; Hydroxydopa

1986